Transcriptional activity of heparan sulfate biosynthetic machinery is specifically impaired in benign prostate hyperplasia and prostate cancer

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Suhovskih, Anastasia V ^a,b   Tsidulko, Alexandra Y ^a   Kutsenko, Olesya S ^a   Kovner, Anna V ^c   Aidagulova, Svetlana V ^d   Ernberg, Ingemar ^e   Grigorieva, Elvira V ^a,e  

^a INSTITUTE OF MOLECULAR BIOLOGY AND BIOPHYSICS   (Russian Federation)

^b NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^c Research Institute of Experimental and Clinical Medicine   (Russian Federation)

^d NOVOSIBIRSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biosynthesis; Expression; Heparan sulfate; Prostate cancer; Proteoglycan; Transcriptional pattern

Indexed keywords

HEPARAN SULFATE;

ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT;

EID: 84901049570     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00079     Document Type: Article

References (42)

1. Lander AD, Selleck SB. The elusive functions of proteoglycans: in vivo veritas. J Cell Biol (2000) 148(2):227-32. doi:10.1083/jcb.148.2.227.
2. Couchman JR, Pataki CA. An introduction to proteoglycans and their localization. J Histochem Cytochem (2012) 60(12):885-97. doi:10.1369/0022155412464638.
3. Dreyfuss JL, Regatieri CV, Jarrouge TR, Cavalheiro RP, Sampaio LO, Nader HB. Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. An Acad Bras Cienc (2009) 81(3):409-29. doi:10.1590/S0001-37652009000300007.
4. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol (2001) 11(2):75-82. doi:10.1016/S0962-8924(00)01897-3.
5. Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CL, Dierks T. The heparanome-the enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol (2007) 129(2):290-307. doi:10.1016/j.jbiotec.2007.01.022.
6. Muthana SM, Campbell CT, Gildersleeve JC. Modifications of glycans: biological significance and therapeutic opportunities. ACS Chem Biol (2012) 7(1):31-43. doi:10.1021/cb2004466.
7. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature (2007) 446(7139):1030-7. doi:10.1038/nature05817.
8. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 15(5):1013-31. doi:10.1111/j.1582-4934.2010.01236.x.
9. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J (2012) 279(7):1177-97. doi:10.1111/j.1742-4658.2012.08529.x.
10. Lindahl U, Kjellén L. Pathophysiology of heparan sulphate: many diseases, few drugs. J Intern Med (2013) 273(6):555-71. doi:10.1111/joim.12061.
11. Edwards IJ. Proteoglycans in prostate cancer. Nat Rev Urol (2012) 9(4):196-206. doi:10.1038/nrurol.2012.19.
12. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem (2002) 71:435-71. doi:10.1146/annurev.biochem.71.110601.135458.
13. Kreuger J, Kjellén L. Heparan sulfate biosynthesis: regulation and variability. J Histochem Cytochem (2012) 60(12):898-907. doi:10.1369/0022155412464972.
14. Presto J, Thuveson M, Carlsson P, Busse M, Wilén M, Eriksson I, et al. Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation. Proc Natl Acad Sci U S A (2008) 105(12):4751-6. doi:10.1073/pnas.0705807105.
15. Dagälv A, Holmborn K, Kjellén L, Abrink M. Lowered expression of heparan sulfate/heparin biosynthesis enzyme N-deacetylase/n-sulfotransferase 1 results in increased sulfation of mast cell heparin. J Biol Chem (2011) 286(52):44433-40. doi:10.1074/jbc.M111.303891.
16. Ropero S, Setien F, Espada J, Fraga MF, Herranz M, Asp J, et al. Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells. Hum Mol Genet (2004) 13(22):2753-65. doi:10.1093/hmg/ddh298.
17. Hameetman L, David G, Yavas A, White SJ, Taminiau AH, Cleton-Jansen AM, et al. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol (2007) 211(4):399-409. doi:10.1002/path.2127.
18. Bret C, Hose D, Reme T, Sprynski AC, Mahtouk K, Schved JF, et al. Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol (2009) 145(3):350-68. doi:10.1111/j.1365-2141.2009.07633.x.
19. Tzeng ST, Tsai MH, Chen CL, Lee JX, Jao TM, Yu SL, et al. NDST4 is a novel candidate tumor suppressor gene at chromosome 4q26 and its genetic loss predicts adverse prognosis in colorectal cancer. PLoS One (2013) 8(6):e67040. doi:10.1371/journal.pone.0067040.
20. Grigorieva E, Eshchenko T, Rykova VI, Chernakov A, Zabarovsky E, Sidorov SV. Decreased expression of human D-glucuronyl C5-epimerase in breast cancer. Int J Cancer (2008) 122(5):1172-6. doi:10.1002/ijc.23203.
21. Prudnikova TY, Mostovich LA, Domanitskaya NV, Pavlova TV, Kashuba VI, Zabarovsky ER, et al. Antiproliferative effect of D-glucuronyl C5-epimerase in human breast cancer cells. Cancer Cell Int (2010) 10:2. doi:10.1186/1475-2867-10-27.
22. Grigorieva EV, Prudnikova TY, Domanitskaya NV, Mostovich LA, Pavlova TV, Kashuba VI, et al. D-Glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo. Br J Cancer (2011) 105(1):74-82. doi:10.1038/bjc.2011.170.
23. Prudnikova TY, Soulitzis N, Kutsenko OS, Mostovich LA, Haraldson K, Ernberg I, et al. Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer. Cancer Med (2013) 2(5):654-61. doi:10.1002/cam4.108.
24. Rosenberg EE, Prudnikova TY, Zabarovsky ER, Kashuba VI, Grigorieva EV. D-glucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells. Tumour Biol (2014) 35(4):3237-45. doi:10.1007/s13277-013-1423-6.
25. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene (2007) 26(34):4969-78. doi:10.1038/sj.onc.1210300.
26. Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol (2008) 4(6):803-14. doi:10.2217/14796694.4.6.803.
27. Rosen SD, Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets (2010) 14(9):935-49. doi:10.1517/14728222.2010.504718.
28. Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L, Shafat I, et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res (2008) 49(3):207-10. doi:10.1080/03008200802143281.
29. Sanderson RD, Iozzo RV. Targeting heparanase for cancer therapy at the tumor-matrix interface. Matrix Biol (2012) 31(5):283-4. doi:10.1016/j.matbio.2012.05.001.
30. Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, et al. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol (2010) 4(2):98-118. doi:10.1016/j.molonc.2009.12.001.
31. Fernández-Vega I, García O, Crespo A, Castañón S, Menéndez P, Astudillo A, et al. Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer. BMC Cancer (2013) 13:24. doi:10.1186/1471-2407-13-24.
32. Tátrai P, Egedi K, Somorácz A, van Kuppevelt TH, Ten Dam G, Lyon M, et al. Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem (2010) 58(5):429-41. doi:10.1369/jhc.2010.955161.
33. Feta A, Do AT, Rentzsch F, Technau U, Kusche-Gullberg M. Molecular analysis of heparan sulfate biosynthetic enzyme machinery and characterization of heparan sulfate structure in Nematostella vectensis. Biochem J (2009) 419(3):585-93. doi:10.1042/BJ20082081.
34. Yabe T, Hata T, He J, Maeda N. Developmental and regional expression of heparan sulfate sulfotransferase genes in the mouse brain. Glycobiology (2005) 15(10):982-93. doi:10.1093/glycob/cwi090.
35. Coulson-Thomas VJ, Gesteira TF, Coulson-Thomas YM, Vicente CM, Tersariol IL, Nader HB, et al. Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-β, and extracellular matrix down-regulation. Exp Cell Res (2010) 316(19):3207-26. doi:10.1016/j.yexcr.2010.08.005.
36. Freeman MR, Song Y, Carson DD, Guthrie PD, Chung LW. Extracellular matrix and androgen receptor expression associated with spontaneous transformation of rat prostate fibroblasts. Cancer Res (1991) 51(7):1910-6.
37. Chung LW. Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Cancer Metastasis Rev (1991) 10(3):263-74. doi:10.1007/BF00050797.
38. McCormick C, Duncan G, Goutsos KT, Tufaro F. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci U S A (2000) 97(2):668-73. doi:10.1073/pnas.97.2.668.
39. Dejima K, Takemura M, Nakato E, Peterson J, Hayashi Y, Kinoshita-Toyoda A, et al. Analysis of Drosophila glucuronyl C-5 epimerase: implications for developmental roles of heparan sulfate sulfation compensation and 2-O sulfated glucuronic acid. J Biol Chem (2013) 288(48):34384-93. doi:10.1074/jbc.M113.499269.
40. Österholm C, Lu N, Lidén Å, Karlsen TV, Gullberg D, Reed RK, et al. Fibroblast EXT1-levels influence tumor cell proliferation and migration in composite spheroids. PLoS One (2012) 7(7):e41334. doi:10.1371/journal.pone.0041334.
41. Osterholm C, Barczyk MM, Busse M, Grønning M, Reed RK, Kusche-Gullberg M. Mutation in the heparan sulfate biosynthesis enzyme EXT1 influences growth factor signaling and fibroblast interactions with the extracellular matrix. J Biol Chem (2009) 284(50):34935-43. doi:10.1074/jbc.M109.005264.
42. Nadanaka S, Zhou S, Kagiyama S, Shoji N, Sugahara K, Sugihara K, et al. EXTL2, a member of the EXT family of tumor suppressors, controls glycosaminoglycan biosynthesis in a xylose kinase-dependent manner. J Biol Chem (2013) 288(13):9321-33. doi:10.1074/jbc.M112.416909.